期刊
ANTIBODIES
卷 9, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/antib9020016
关键词
antibody drug conjugate; site-specific conjugation; hydrophobic interaction chromatography (HIC) purification; AJICAP (TM)
类别
资金
- Ajinomoto Co., Inc.
In recent years, site-specific antibody drug conjugates (ADC)s have been in great demand because they have an expanded therapeutic index compared with conventional ADCs. AJICAP (TM) technology is a chemical conjugation platform to obtain site-specific ADCs through the use of a class of Fc-affinity compounds. Promising results from early technology development studies led to further investigation of AJICAP (TM) ADC materials to obtain site-specific and homogeneous drug antibody ratio (DAR) ADCs. Here we report site-specific conjugation followed by a preparative hydrophobic interaction chromatography (HIC) purification strategy to obtain purified DAR = 1.0 and DAR = 2.0 AJICAP (TM) ADC materials. Optimization of the mobile phase conditions and resin achieved a high recovery rate. In vitro biological assay demonstrated the target selective activity for purified homogeneous DAR ADCs. These results indicate the ability of a HIC purification strategy to provide DAR = 1.0 and DAR = 2.0 AJICAP (TM) ADCs with considerable potency and target selectivity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据